INTERVIEW: ImmunoGen prepares to capitalize on Kadcyla
This article was originally published in Scrip
Executive Summary
ImmunoGen is preparing to capitalize on US FDA approval in February for Kadcyla (ado trastuzumab emtansine) - the first approved cancer therapy that incorporates the Waltham, Massachusetts-based company's antibody-drug conjugate (ADC) technology.